COVID-19 convalescent plasma will be infused to patients with severe COVID-19 pneumonia to determine feasibility, safety and clinical outcome efficacy by survival at-28 days. Data will be compared with match control arm patients without plasma infusion
To determinate feasibility, safety and outcome with convalescent plasma in patients with severe COVID-19 penumonia